Lipocine Inc. (LPCN) Stock Price

LPCNStock

$1.56−49.84%52W

Market Cap$12.86M

P/E6416.73x

PEG Ratio—

Div yield—

Beta0.43

LPCN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-48.25%

Price vs S&P 500 (4W)-29.03%

VGM Score49.17

P/E Ratio (Annual)6416.73x

Book Value / Share (Quarterly)$2.64

P/TBV (Annual)0.37x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)58.12%

Cash Flow / Share (Quarterly)$-1.36

Price vs S&P 500 (YTD)-92.50%

Net Profit Margin (TTM)-755.13%

EPS (TTM)$-1.87

10-Day Avg Trading Volume11.17M

EPS Excl Extra (TTM)$-1.87

Revenue Growth (5Y)133.89%

EPS (Annual)$-1.77

ROI (Annual)-66.50%

Net Profit Margin (5Y Avg)-2154.83%

Cash / Share (Quarterly)$2.82

Revenue Growth QoQ (YoY)-69.48%

P/E Normalized (Annual)6416.73x

ROA (Last FY)-56.61%

Revenue Growth TTM (YoY)-62.70%

EBITD / Share (TTM)$-1.92

ROE (5Y Avg)-35.66%

Operating Margin (TTM)-800.82%

Cash Flow / Share (Annual)$-1.58

P/B Ratio0.59x

P/B Ratio (Quarterly)0.97x

Net Income / Employee (Annual)$-687,700

EV / Revenue (TTM)5.02x

Net Interest Coverage (TTM)-3.50x

ROA (TTM)-57.62%

EV / EBITDA (TTM)2.26x

EPS Incl Extra (Annual)$-1.77

Current Ratio (Annual)6.68x

Quick Ratio (Quarterly)11.39x

3-Month Avg Trading Volume1.29M

52-Week Price Return-49.84%

Revenue / Employee (TTM)$112,100

Tangible BV / Share (Quarterly)$4.23

P/S Ratio (Annual)6.51x

Asset Turnover (Annual)0.12x

52-Week High$12.37

Operating Margin (5Y Avg)-2195.35%

EPS Excl Extra (Annual)$-1.77

Tangible BV CAGR (5Y)13.43%

26-Week Price Return-38.34%

Quick Ratio (Annual)6.36x

13-Week Price Return-30.04%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)11.48x

Enterprise Value$7.88M

Revenue / Share Growth (5Y)81.34%

Asset Turnover (TTM)0.08x

Book Value / Share Growth (5Y)-8.79%

Revenue / Employee (Annual)$141,200

Pretax Margin (Annual)-487.04%

Cash / Share (Annual)$2.42

3-Month Return Std Dev51.40%

Net Income / Employee (TTM)$-846,500

ROE (Last FY)-66.50%

Net Interest Coverage (Annual)-3.57x

EPS Basic Excl Extra (Annual)$-1.77

P/FCF (TTM)3.14x

Receivables Turnover (TTM)14.09x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.87

Receivables Turnover (Annual)29.36x

ROI (TTM)-64.75%

P/S Ratio (TTM)8.19x

Pretax Margin (5Y Avg)-2154.82%

Revenue / Share (Annual)$0.36

Tangible BV / Share (Annual)$6.84

Price vs S&P 500 (52W)-65.37%

Year-to-Date Return-80.57%

5-Day Price Return-6.02%

EPS Normalized (Annual)$-1.77

ROA (5Y Avg)-31.50%

Net Profit Margin (Annual)-487.05%

Month-to-Date Return-29.09%

Cash Flow / Share (TTM)$-3.09

EBITD / Share (Annual)$-1.89

Operating Margin (Annual)-524.69%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-35.65%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.87

P/TBV (Quarterly)0.59x

P/B Ratio (Annual)3.08x

Pretax Margin (TTM)-755.11%

Book Value / Share (Annual)$2.35

Price vs S&P 500 (13W)-32.73%

Beta0.43x

Revenue / Share (TTM)$0.19

ROE (TTM)-64.75%

52-Week Low$1.48

vGradeB

gGradeD

mGradeD

vgmGradeC

LPCN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 4, 2026	-$0.40	-$0.32	+20.00%(+$0.08)
Q1 2026	May 7, 2026	-$0.48	-$0.54	-11.34%(-$0.06)
Q4 2025	Mar 10, 2026	-$0.61	-$0.42	+31.15%(+$0.19)
Q3 2025	Nov 6, 2025	-$0.54	-$0.59	-9.26%(-$0.05)
Q2 2025	Aug 5, 2025	-$0.40	-$0.41	-2.50%(-$0.01)

LPCN Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.00

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
LPCNLipocine Inc.	B	D	D	8.2x	-62.7%	—	—	$1.56
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Lipocine Inc.

Lipocine is a clinical-stage biopharmaceutical company developing oral drug delivery solutions using proprietary technology. Its lead product, TLANDO, is an oral testosterone replacement therapy. The company is advancing a pipeline of additional candidates including TLANDO XR and compounds designated LPCN 1144, LPCN 1148, LPCN 1107, and LPCN 1154, developed both internally and in collaboration with corporate partners.

LPCN Insider Transactions

BuySep 28, 2026
HIGUCHI JOHN W
Director
Shares: 12,561Value: $27,132

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

TCRXTScan Therapeutics, Inc. Common StockBiological Products
TOMZTOMI Environmental Solutions, Inc.Industrial Chemicals
BCDABioCardia, Inc. Common StockBiological Products
MTEXMannatech Inc.Pharmaceutical Preparations
CABRCaring Brands, Inc. Common StockCosmetics & Toiletries
PLURPluri Inc. Common StockBiological Products
PASGPassage Bio, Inc. Common StockBiological Products
INABIN8bio, Inc. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.0

Buy

Consensus rating

52-Week Range

Low$1.48

High$12.37